Clinical Evaluation of the Use of Surgical Tube Technique Versus Hyaluronic AcidInjection in Reconstruction of the Interproximal Papilla
the Clinical Effect of Surgical Tube Technique in Reconstruction of the Interproximal Papilla

About this trial
This is an interventional treatment trial for the Clinical Effect of Surgical Tube Technique in Reconstruction of the Interproximal Papilla
Eligibility Criteria
Inclusion Criteria:
Highly motivated patients with papillary deficiency types II, according to Nordland and Tarnow 1998 classification will be selected, having at least one deficient papilla in the anterior region.
- Distance between the contact point and inter-proximal bone crest (CP-BC) of ≤ 7 mm and probing depth of ≤ 4 mm at the deficient papillary site (Abdelraouf etal. 2019).
- Patients with full mouth plaque index (PI) and gingival index (GI) scores should be between 0-1.
- Healthy patients free of any medical condition.
Exclusion Criteria:
● Patients with medical conditions that may affect periodontal healing or regeneration.
- Patients with a history of allergic reactions, pregnant or breastfeeding females, smokers and alcoholics.
- Patients with current or previous drugs intake that may predispose to gingival enlargement.
- Patients under orthodontic treatment or had orthodontic treatment in the past six months.
- Carious teeth, proximal restorations or fixed prosthesis.
- Patients with a history of traumatic oral hygiene measures or periodontal surgeries over the last six months at the area of interest or having any scar tissue.
- Poor oral hygiene patients.
Sites / Locations
- Waleed Mohammad SabryRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Tube technique.
Hyaluronic acid.
The excavator is used to do the same on the palatal aspect. The recipient site at this time should resemble a "tube" with two openings; one on the buccal aspect at the mucogingival junction and one on the palatal aspect. To harvest the graft, the incision is made parallel to and 2 mm away from the gingival margin. A thin flap containing the keratinized tissue is separated, then the second incision is made parallel to the gingival margin, but perpendicular to the alveolar bone. With a sharp periosteal elevator, the graft is raised with the periosteum and released at its anterior and posterior ends, and then from its base .
The product used in this trial is Restylane Lidocaine (Restylane-Lidocaine cross-linked Hyaluronic Acid Filler, Galderma S.A, Sweden). Restylane was the first FDA-approved HA filler in 2003. Restylane is a non-animal stabilised cross-linked HA filler with an HA concentration of 20 mg/ml. It is a minimally invasive non-surgical injection of hyaluronic acid that observed to overcome the major limiting factor in most surgical techniques regarding the limited blood supply and the small working space. Supported by a recent study conducted by Jinng etal. 2019, who reported significant increase in the height of the gingival papilla and reduction of the area of the black triangle between baseline and 3 or 6 months in a group with thick gingival biotype after injection with hyaluronic acid, that was adding possible maximum effect with minimal postoperative hazards.